U.S., June 4 -- ClinicalTrials.gov registry received information related to the study (NCT07002177) titled 'A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC' on May 14.
Brief Summary: This is a Study to Evaluate the Efficacy and Safety of Multiple Combination Therapies with FWD1802 in Subjects with ER-positive/HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer
Study Start Date: June 01
Study Type: INTERVENTIONAL
Condition:
Metastatic Breast Cancer
Breast Cancer Stage I
Breast Cancer Stage II
Locally Advanced Breast Cancer (LABC)
ER+ Breast Cancer
Intervention:
DRUG: FWD1802
orally QD with 28 days each cycle, treatment till disease progression or intolerable ...